ReviewIntestinal Failure (New York, N.Y.)
The current state of paediatric intestinal transplantation: A global review.
Review in Intestinal Failure (New York, N.Y.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Paediatric intestinal transplantation (ITx) has evolved from a high-risk experimental procedure into a life-saving therapy for children who have complications of intestinal failure (IF) or who cannot be stabilized by nutritional rehabilitation. Indications include complications of irreversible intestinal failure from short bowel syndrome, motility disorders, or intestinal dysplasia, with graft options ranging from isolated intestine to liver-intestine or multivisceral transplantation, including reduced-size and living donor grafts. Advances in surgical techniques, perioperative care, and immunosuppression have markedly improved survival and functional outcomes, although early and late graft loss, rejection, and infectious complications remain important challenges. Optimized immunosuppression protocols have reduced acute rejection rates, but also facilitated successful retransplantation when required. Multidisciplinary management addressing growth, neurodevelopment, and psychosocial well-being is recognized as being essential for improving long-term quality of life. Despite these advances, significant global disparities persist in access to paediatric ITx, driven by donor scarcity, financial constraints, and limited expertise in low-resource regions. Collaborative networks, telemedicine platforms, and international registries have emerged to share knowledge, standardize care, and support capacity-building. Looking forward, advancements in immunosuppression, expanded living donor programmes and international collaboration hold promise for further improving outcomes and broadening access. Increasing recognition of the benefits of earlier referral and transplantation is shifting the paradigm from viewing ITx solely as a rescue therapy toward proactive management to optimize survival, growth, and quality of life. Collectively, these developments indicate a future in which paediatric ITx offers not only life-saving treatment but also enhanced long-term health, improved quality of life, and equitable access for children worldwide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.